Rhumbline Advisers Standard Biotools Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Standard Biotools Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 370,514 shares of LAB stock, worth $414,975. This represents 0.0% of its overall portfolio holdings.

Number of Shares

370,514

Previous 381,489 2.88%

Holding current value

$414,975

Previous $736,000 11.96%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$1.5 - $2.26 $16,462 - $24,803	-10,975 Reduced 2.88%	370,514 $648,000
Q3 2024 Nov 12, 2024	SELL	$1.42 - $2.35 $36,888 - $61,048	-25,978 Reduced 6.38%	381,489 $736,000
Q2 2024 Aug 01, 2024	BUY	$1.65 - $2.92 $654,586 - $1.16 Million	396,719 Added 3691.1%	407,467 $721,000
Q1 2024 May 09, 2024	BUY	$1.87 - $2.78 $14,692 - $21,842	7,857 Added 271.77%	10,748 $29,000
Q2 2023 Aug 08, 2023	BUY	$1.47 - $2.56 $4,249 - $7,400	2,891 New	2,891 $5,000
Q2 2022 Aug 11, 2022	SELL	$1.6 - $3.99 $153,614 - $383,075	-96,009 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.8 - $3.96 $22,968 - $32,483	-8,203 Reduced 7.87%	96,009 $345,000
Q4 2021 Feb 10, 2022	SELL	$3.63 - $6.13 $4,773 - $8,060	-1,315 Reduced 1.25%	104,212 $409,000
Q3 2021 Nov 12, 2021	BUY	$5.5 - $7.41 $13,392 - $18,043	2,435 Added 2.36%	105,527 $695,000
Q2 2021 Aug 05, 2021	SELL	$4.35 - $6.35 $44,374 - $64,776	-10,201 Reduced 9.0%	103,092 $635,000
Q1 2021 May 06, 2021	SELL	$3.94 - $7.09 $16,784 - $30,203	-4,260 Reduced 3.62%	113,293 $512,000
Q4 2020 Feb 10, 2021	BUY	$5.45 - $8.65 $82,807 - $131,428	15,194 Added 14.84%	117,553 $705,000
Q3 2020 Nov 12, 2020	SELL	$4.34 - $11.43 $70,742 - $186,309	-16,300 Reduced 13.74%	102,359 $761,000
Q2 2020 Aug 13, 2020	BUY	$1.85 - $5.29 $65,663 - $187,763	35,494 Added 42.68%	118,659 $476,000
Q1 2020 May 06, 2020	SELL	$1.24 - $4.35 $813 - $2,853	-656 Reduced 0.78%	83,165 $211,000
Q4 2019 Feb 05, 2020	SELL	$2.3 - $5.12 $517 - $1,152	-225 Reduced 0.27%	83,821 $292,000
Q3 2019 Oct 23, 2019	SELL	$4.63 - $12.15 $203 - $534	-44 Reduced 0.05%	84,046 $389,000
Q2 2019 Aug 14, 2019	BUY	$11.49 - $14.17 $499,895 - $616,494	43,507 Added 107.2%	84,090 $1.04 Million
Q1 2019 May 01, 2019	BUY	$8.47 - $14.36 $51,616 - $87,509	6,094 Added 17.67%	40,583 $539,000
Q4 2018 Jan 31, 2019	BUY	$7.18 - $8.83 $74,370 - $91,461	10,358 Added 42.92%	34,489 $297,000
Q3 2018 Nov 07, 2018	SELL	$5.92 - $8.35 $9,620 - $13,568	-1,625 Reduced 6.31%	24,131 $181,000
Q2 2018 Aug 06, 2018	SELL	$4.86 - $6.24 $37,373 - $47,985	-7,690 Reduced 22.99%	25,756 $154,000
Q1 2018 May 02, 2018	BUY	$5.75 - $7.97 $31,653 - $43,874	5,505 Added 19.7%	33,446 $195,000
Q4 2017 Feb 09, 2018	SELL	$4.46 - $6.45 $14,486 - $20,949	-3,248 Reduced 10.41%	27,941 $165,000
Q3 2017 Nov 06, 2017	BUY	$3.55 - $5.49 $110,720 - $171,227	31,189	31,189 $157,000

Others Institutions Holding LAB

# of Institutions

144

Shares Held

274M

Call Options Held

6.7K

Put Options Held

48.7K

View Full List

About STANDARD BIOTOOLS INC.

Ticker LAB
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 78,654,800
Market Cap $88.1M
Description
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...

More about LAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Standard Biotools Inc. Transaction History